Diabetes:
Indications for: BAQSIMI
Severe hypoglycemia.
Adults and Children:
<4yrs: not established. ≥4yrs: 3mg as single spray intranasally into one nostril. May repeat with new device after 15mins if no response. The dose does not require inhalation.
BAQSIMI Contraindications:
Pheochromocytoma. Insulinoma.
BAQSIMI Warnings/Precautions:
Increased blood pressure. Previously undiagnosed pheochromocytoma. Lack of efficacy in insulinoma; may cause hypoglycemia. Insufficient hepatic glycogen stores (eg, starvation, adrenal insufficiency, chronic hypoglycemia); treat with glucose. Pregnancy. Nursing mothers.
BAQSIMI Classification:
Antihypoglycemic.
BAQSIMI Interactions:
Transient increase in pulse and blood pressure may occur with beta-blockers. Loss of efficacy or may produce hypoglycemia with indomethacin. May potentiate the anticoagulant effect of warfarin.
Adverse Reactions:
Nausea, headache, vomiting, upper respiratory tract irritation (eg, rhinorrhea, nasal discomfort/congestion, cough, epistaxis), watery eyes, redness of eyes, itchy nose/throat/eyes; allergic reactions.
Generic Drug Availability:
NO
How Supplied:
Pack—1, 2
